Pharma Stability: Insights, Guidelines, and Expertise
Before attempting to justify study continuation, it is essential that your stability protocol clearly defines what constitutes a “significant deviation”. Common examples include:
Click to read the full article.
Excursions — deviations from specified environmental conditions in stability chambers — can compromise the reliability of stability data and product quality. While a single deviation may be justifiable, regulators scrutinize recurrence trends to identify deeper process failures.
Click to read the full article.
Excursions, especially in stability chambers, may impact the validity of stability data. Regulatory bodies are increasingly raising concerns over not just individual deviations, but over trends of recurring events. If a chamber crosses the specified 25°C/60% RH or 30°C/65% RH range multiple times in a quarter, it is seen as a red flag.
Click to read the full article.
In the tightly regulated pharmaceutical industry, it’s not enough to just initiate corrective and preventive actions (CAPA) — you must prove they are effective. In stability operations, especially where temperature excursions or equipment deviations can jeopardize long-term data, effective CAPA monitoring ensures the integrity of your product shelf-life determinations. Regulatory bodies like USFDA and EMA scrutinize how you track CAPAs and assess their impact across the product lifecycle.
Click to read the full article.
In the pharmaceutical industry, stability excursions can directly compromise the integrity of long-term data, and therefore, the shelf-life claims of a product. Whenever a deviation such as a temperature or humidity excursion is identified, an effective investigation must not only find the cause — it must categorize the root cause appropriately. Regulatory agencies, including USFDA and EMA, demand documented justification for both the cause and the classification.
Click to read the full article.
In today’s globalized pharmaceutical operations, companies often manage manufacturing and stability testing activities across multiple facilities or contract partners. When a deviation occurs—whether during sample storage, data logging, or chamber control—it may involve more than one site. Managing such stability-related deviations consistently across all locations is critical for regulatory compliance and product integrity.
Click to read the full article.
In the pharmaceutical industry, not all deviations pose the same threat to product quality, patient safety, or data integrity. A minor oversight during documentation and a temperature excursion in a stability chamber cannot be treated with equal urgency. This is where the principles of ICH Q9 — Quality Risk Management (QRM) — come into play, helping organizations systematically assess, prioritize, and respond to deviations based on risk.
Click to read the full article.
Corrective and Preventive Actions (CAPA) form a critical part of pharmaceutical quality systems, especially within the context of stability studies. These actions not only address current deviations but also prevent future occurrences by targeting systemic issues. However, unless thoroughly reviewed, even a well-documented CAPA plan may fall short of regulatory expectations.
Click to read the full article.
Outsourcing stability studies is a strategic move in pharmaceutical development, especially when internal resources are limited or specialized testing environments are needed. However, entrusting your product’s long-term data to a third-party lab or storage facility introduces risk. That’s why a thorough vendor qualification process is not optional — it’s a regulatory requirement under GMP and ICH guidelines.
Click to read the full article.
In the pharmaceutical industry, outsourcing stability studies to Contract Research Organizations (CROs) or contract labs is a common practice to optimize resources and leverage specialized infrastructure. However, this comes with inherent compliance risks. Regulatory agencies like CDSCO and EMA emphasize the need for clear, legally binding quality agreements that define roles, responsibilities, and expectations between the sponsor and the CRO.
Click to read the full article.